Small Molecules

Amgen is propelling the next generation of targeted small molecules, leveraging our deep knowledge of the human and cancer genome to improve treatment outcomes.

$name
$name

Oncology

The Precision Medicine Revolution in NSCLC: Featuring Dr. Suresh Ramalingam, Deputy Director, Winship Cancer Institute of Emory University

VIEW VIDEO
Arrow
❮1 / 2❯
$name
$name

Oncology

Perspectives from the Community: A Fireside Chat with Andrea Ferris, President and CEO of LUNGevity

VIEW VIDEO
Arrow
❮2 / 2❯

KRAS

KRAS is one of the most common driver mutations in non-small cell lung cancer (NSCLC), and nearly 50% of all KRAS mutations in the U.S. are KRAS G12C.1,2,3As the first to drug the KRAS mutation, we continue to advance CodeBreaK – the broadest and most comprehensive global clinical development program for patients with the KRAS G12C mutation – that will allow us to understand where we can best serve patients whose solid tumors harbor this mutation.

References

  1. Pakkala S, et al. JCI Insight. 2018:e120858.
  2. Arbour KC, et al. Clin Cancer Res. 2018;24:334-340.
  3. Cox AD, et al. Nat Rev Drug Discov. 2014;13:828-851.